AtriCure (ATRC) vs Envista (NVST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AtriCure (ATRC) has outperformed Envista (NVST) over the past year, gaining 56.2% versus a gain of 12.8%. Over five years, ATRC leads with a -25.3% price change compared with -40.5% for NVST. Envista is the larger company by market cap ($3.60 billion vs $2.67 billion), about 1.3 times the size, while AtriCure is growing revenue faster (+14.9% vs +8.3%).
On valuation, Envista trades at a lower forward P/E (13.5x vs 121.0x for AtriCure). Envista converts more of its revenue into profit, with a net margin of 1.7% versus -2.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | NVST |
|---|---|---|
| Share price | $52.53 | $22.44 |
| Market cap | $2.67B | $3.60B |
| 1-day change | -1.46% | -2.60% |
| YTD return | +34.76% | +6.13% |
| 1-year return | +56.24% | +12.83% |
| 5-year return | -25.30% | -40.50% |
| P/E ratio (TTM) | 250.14 | 38.69 |
| Forward P/E | 121.04 | 13.48 |
| EPS (TTM) | $0.21 | $0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $534.53M | $2.72B |
| Revenue growth (YoY) | +14.88% | +8.32% |
| Net income (latest FY) | $-11.45M | $47.00M |
| Gross margin | 74.98% | 54.67% |
| Operating margin | -1.77% | 7.95% |
| Net margin | -2.14% | 1.73% |
| 52-week high | $61.70 | $30.42 |
| 52-week low | $25.36 | $18.77 |
| Distance from 52-week high | -14.86% | -26.23% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +4.49% | +32.31% |
| Average volume | 1.09M | 2.81M |
| Shares outstanding | 50.87M | 160.62M |
| Employees | 1,350 | 12,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRC has outperformed NVST by 43.4 percentage points over the past year.
- AtriCure trades at a higher earnings multiple (250.1x vs 38.7x trailing P/E).
- AtriCure grew revenue faster in its latest fiscal year (+14.88% vs +8.32%).
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About Envista
NVST stock →Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables.
Health Care · Medical/Dental Instruments · 12,000 employees
ATRC vs NVST FAQ
Which is bigger, AtriCure or Envista?
Envista (NVST) is larger, with a market capitalization of $3.60B compared with $2.67B for AtriCure (ATRC).
Which stock has performed better over the past year, ATRC or NVST?
ATRC returned +56.24% over the past 12 months, compared with +12.83% for NVST (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ATRC or NVST?
NVST has the lower trailing P/E at 38.7, versus 250.1 for ATRC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are AtriCure and Envista in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.